Skip to content

Author

A. Gwóźdź-Broczkowska

We have 2 of 14 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

AI-generated patient instructions as safety-critical communication: a provisional evidence-informed framework for clinical deployment.

Generative artificial intelligence (AI) can convert clinical information into patient-facing instructions, including discharge summaries, medication explanations, portal messages and plain-language educational materials. These outputs may improve accessibility and reduce documentation burden. They also create a distinct patient-safety problem: patients may act on fluent, incomplete, or contextually unsafe instructions without the clinical knowledge required to detect error. Early evaluations show a recurring trade-off. Large language models can improve readability and understandability of discharge information, yet physician and pharmacist review has identified omissions, inaccuracies, newly introduced actions, medication-related problems and potentially harmful safety issues, particularly in complex discharge contexts. This narrative and interpretative review reframes AI-generated patient instructions as a safety-critical informatics intervention rather than a language-simplification tool. A targeted literature mapping was undertaken across empirical studies of AI-generated discharge communication, health-literacy and medication-safety literature, patient-safety evidence, and emerging artificial-intelligence governance frameworks. I propose a sevendomain safety framework covering factual accuracy, clinical completeness, actionability, medication clarity, escalation and safety-netting, health-literacy alignment, and accountability with auditability. The framework is intended to support implementation, local evaluation and reviewer assessment rather than to function as a formal consensus guideline. High-risk patient-facing outputs require accountable clinical workflows, with human verification, traceability, equity testing and post-deployment monitoring. Before wider use, evaluation needs to assess not only readability, but also comprehension, actionability and potential harm.

A. Gwóźdź-Broczkowska · 0 citations
Review Open access Aug 2026

PLASMA p-tau217 AS A MINIMALLY INVASIVE BIOMARKER FOR ALZHEIMER’S DISEASE DIAGNOSIS: ANALYTICAL PLATFORMS, DIAGNOSTIC PERFORMANCE, AND CLINICAL IMPLEMENTATION CHALLENGES

Plasma p-tau217 showed high diagnostic performance for identifying amyloid and tau pathology and generally outperformed other phosphorylated tau isoforms, but it should not be interpreted as a stand-alone test.

Oliwia Lenkiewicz, Julia Lenkiewicz, Z. Chmielewska et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.